Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546960 · ClinicalTrials.gov registry record · Phase 2
A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 848
- Enrollment target
NCT02546960 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 848 participants.
The verdict
NCT02546960, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 848 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability of different doses of JNJ-63871860 (ExPEC4V) in participants greater than or equal to (\>=)18 years of age and to evaluate the dose-dependent immunogenicity of ExPEC as measured by enzyme-linked immunosorbent assay (ELISA).
Interventions
- BIOLOGICAL ExPEC4V (4 : 4 : 4 : 4)
- BIOLOGICAL ExPEC4V (4 : 4 : 4 : 8)
- BIOLOGICAL ExPEC4V (8 : 8 : 8 : 8)
- BIOLOGICAL ExPEC4V (8 : 8 : 8 : 16)
- BIOLOGICAL ExPEC4V (16 : 16 : 16 : 16)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 848 participants |
| Start Date | 2015-11-12 |
| Est. Completion | 2019-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02546960
The ClinicalTrials.gov registry entry for NCT02546960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 848 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ExPEC4V (4 : 4 : 4 : 4) is the first listed.
NCT02546960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02546960 about?
NCT02546960 is a clinical study titled "A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860". The purpose of this study is to evaluate the safety, tolerability of different doses of JNJ-63871860 (ExPEC4V) in participants greater than or equal to (\>=)18 years of age and to evaluate the dose-dependent immunogenicity of ExPEC as measured by enzyme-linked immunosorbent assay (ELISA).
What is the current status of trial NCT02546960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 848 participants. The study started on 2015-11-12. Estimated completion is 2019-06-21.
What interventions are being tested in trial NCT02546960?
The interventions under investigation include: ExPEC4V (4 : 4 : 4 : 4) (BIOLOGICAL), ExPEC4V (4 : 4 : 4 : 8) (BIOLOGICAL), ExPEC4V (8 : 8 : 8 : 8) (BIOLOGICAL), ExPEC4V (8 : 8 : 8 : 16) (BIOLOGICAL), ExPEC4V (16 : 16 : 16 : 16) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02546960?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.